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Abstract
Background: Pancreatic cancer is an aggressive cancer with dismal prognosis, urgently necessitating better
biomarkers to improve therapeutic options and early diagnosis. Traditional approaches of biomarker detection that
consider only one aspect of the biological continuum like gene expression alone are limited in their scope and lack
robustness in identifying the key regulators of the disease. We have adopted a multidimensional approach
involving the cross-talk between the omics spaces to identify key regulators of disease progression.
Methods: Multidimensional domain-specific disease signatures were obtained using rank-based meta-analysis of
individual omics profiles (mRNA, miRNA, DNA methylation) related to pancreatic ductal adenocarcinoma (PDAC).
These domain-specific PDAC signatures were integrated to identify genes that were affected across multiple
dimensions of omics space in PDAC (genes under multiple regulatory controls, GMCs). To further pin down the
regulators of PDAC pathophysiology, a systems-level network was generated from knowledge-based interaction
information applied to the above identified GMCs. Key regulators were identified from the GMC network based on
network statistics and their functional importance was validated using gene set enrichment analysis and survival
analysis.
Results: Rank-based meta-analysis identified 5391 genes, 109 miRNAs and 2081 methylation-sites significantly
differentially expressed in PDAC (false discovery rate ≤ 0.05). Bimodal integration of meta-analysis signatures
revealed 1150 and 715 genes regulated by miRNAs and methylation, respectively. Further analysis identified 189
altered genes that are commonly regulated by miRNA and methylation, hence considered GMCs. Systems-level
analysis of the scale-free GMCs network identified eight potential key regulator hubs, namely E2F3, HMGA2, RASA1,
IRS1, NUAK1, ACTN1, SKI and DLL1, associated with important pathways driving cancer progression. Survival analysis
on individual key regulators revealed that higher expression of IRS1 and DLL1 and lower expression of HMGA2,
ACTN1 and SKI were associated with better survival probabilities.
Conclusions: It is evident from the results that our hierarchical systems-level multidimensional analysis approach
has been successful in isolating the converging regulatory modules and associated key regulatory molecules that
are potential biomarkers for pancreatic cancer progression.
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Background
Cancer is a complex disease that leads to dysregulation
of multiple biological processes and pathways at regula-
tory, transcriptional and translational domains of central
dogma. An extensive amount of genomics, proteomics
and epigenetics data has been generated to probe the
role of molecules from these domains in different path-
ways and biological processes involved in cancer patho-
physiology. Most studies have concentrated on the
individual contribution of molecules in disease patho-
physiology, ignoring the interactions between omics data
from different genomics levels. The generation of inte-
grated system-level networks including the molecules
dysregulated at regulatory (miRNA, methylation), tran-
scriptional (genes) and translational (proteins, metabo-
lites) omics levels helps in generating a complex network
dysregulated in the disease. The analysis of this complex
network can shed light on critical pathways and key
molecules driving disease progression.
Pancreatic cancer is a very aggressive form of cancer
with poor diagnosis and dismal prognosis. Of the exo-
crine pancreatic cancers, 95 % are pancreatic ductal
adenocarcinoma (PDAC), with increasing occurrence in
the last decades [1]. Patients are mostly diagnosed at an
advanced stage, resulting in poor response to therapies
including surgical resection, leading to very low (6 %)
5-year survival rates [2]. The probable early clinical
symptoms like thromboembolism and new-onset type II
diabetes occur much earlier, though the symptoms are
not necessarily associated with pancreatic cancer. The
early stage progress of the disease could be much slower
than previously thought, giving patients with early diag-
nosis a much better survival probability [3]. To date, the
diagnosis is based on clinical signs and pathology even
though the early symptoms are vague and non-
definitive. This raises an urgent need for the develop-
ment of reliable diagnostic, prognostic and therapeutic
biomarkers. The availability of diagnostic biomarkers
from peripheral body fluids will enable routine screen-
ing owing to the ease of testing as opposed to the highly
invasive methods used currently for diagnosis, while the
prognostic markers of early stage PDAC will give pa-
tients a better treatment plan and survival chance. In
this context, intensive literature mining efforts have
been made [4, 5] to identify possible candidate bio-
markers in PDAC diagnosis and treatment. These pro-
vide a good starting point to collate the genes identified
as important players in PDAC that could serve as prog-
nostic or diagnostic biomarkers, but also need extensive
filtering and unification with regards to experimental
conditions under which each study was performed. For
example, studies on prognostic or predictive biomarkers
identified from survival analysis are generally done on
patients with specific mutations or patients following
cancer therapy with specific adjuvant therapy. The re-
sult from each study varies with respect to the identified
predictive molecules owing to differences in design
strategy. Also, predictive signatures obtained from stud-
ies have good predictive power for the subset of patients
with a similar disease profile as in the study, but fail in
the other possible disease profiles, namely, different
causal mutations or different adjuvant therapy. This
calls for biomarker identification based on biological be-
havior of genes in PDAC, independent of subpopulation
disease profiles. It also calls for a method to filter genes
manifesting a causal relationship with disease patho-
physiology from the genes being affected by advance-
ment of the disease process.
Another area that needs to be addressed in identifica-
tion of biomarkers in PDAC is the basic biological pro-
cesses affected in PDAC. It has been shown that
dysregulation of multiple genomic spaces occurs in
many cancers and the resultant disease is a culmination
of multiple mutations; dysregulated control mechanisms,
like regulatory microRNAs and epigenetic control; and
dysregulated genes and proteins. The role of small non-
coding microRNAs (miRNA) in regulating gene expres-
sion in cancer is being extensively studied. It has been
shown the oncogenes and tumor suppressor genes are
targets of differentially expressed miRNAs in solid
tumors [6]. Pedersen et al. studied differential DNA
methylation between normal and PDAC samples to
identify epigenetic markers [7]. To understand the
underlying biological process, these changes have to be
taken into consideration as a whole, thus accounting for
the biological cross-talk between these different func-
tional components.
With the availability of data from different omics stud-
ies and large compilations of multi-omics data like Gene
Expression Omnibus (GEO) [8], the International Can-
cer Genome Consortium (ICGC) [9] and The Cancer
Genome Atlas (TCGA) [10], it is now possible to com-
pare and contrast cancer profiles from normal profiles in
multiple omics dimensions. The complex nature of inter-
actions leading to the pathophysiology of cancer war-
rants the use of systems biology-based approaches to
understand the cause–effect relationship between the
dysregulated molecules identified by traditional super-
vised analysis methods. Biological interaction networks
provide insights into the biology that is fundamental to
the disease process. Additionally, biological networks
can help to identify key genes that are critical in patho-
physiological cancer networks, thus leading to biomarker
identification. These key genes (hubs) in the network
regulate a plethora of important functional genes and
their deletion, in many cases, results in lethality [11]. It
has also been illustrated that interactive networks encom-
passing multiple omics domains can provide better insights
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about key regulatory (KR) molecules than individual dys-
regulated gene-based analysis, by taking into consideration
the gene interactions [12]. In this study, we integrated the
information obtained from multiple omics dimensions,
namely, the transcriptome, regulatory miRNA and the epi-
genome, to build a systems-level network to identify the
key molecules associated with PDAC. Further functional
and survival analysis of the identified KR genes clearly
depicted their association with pathways linked to cancer
progression and survival. Additional file 1: Figure S1 shows
a schematic of the methodology used in this study.
Methods
Data collection
Raw data on gene expression, miRNA expression and
DNA methylation were obtained from public repositor-
ies, namely GEO and TCGA, and were normalized using
R statistical software and Bioconductor packages in a
platform-specific manner. Details about all the published
datasets used in this study (accession numbers/references)
can be found in Table 1. The meta-analysis of gene
expression data was based on four published studies
containing PDAC and normal samples. Affymetrix micro-
array data were preprocessed using the Robust Multichip
Average (RMA) method in R statistical platform [13]
using the Bioconductor packages. RMA performed back-
ground adjustment, quantile normalization and final
summarization of oligonucleotides per transcript using
the median polish algorithm [14]. Illumina microarray
data were processed and quantile normalized using the
Lumi package in Bioconductor [15].
The pancreatic cancer miRNA datasets used in this
study are listed in Table 1. Raw data from the Febit plat-
form were normalized using the quantile normalization
method after background correction and summarized
with replicate median using the linear models for micro-
array data (limma) Bioconductor package in R. Data
from NanoString nCounter were processed using the R
package NanoStringNorm [16] using median back-
ground correction and quantile normalization. Agilent
data were normalized using the AgiMicroRna package
from Bioconductor [17, 18] that includes background
correction and quantile normalization. The methylation
data on pancreatic cancer were obtained from GEO and
TCGA (Table 1). The pre-normalized data were median-
centered to remove any batch effects.
Quality control
The quality of the normalized data from Affymetrix gene
expression datasets was assessed using the arrayQuality-
Metrics package from Bioconductor [19]. Individual
array quality was assessed using various quality control
plots including M-A plots, and homogeneity between ar-
rays was determined using boxplots and density estimate
plots. Outliers were identified using heatmaps and den-
drograms based on inter-array expression distances
(mean absolute distance of the M-value for each pair of
arrays). Datasets that did not show any class-based (i.e.,
normal or PDAC) clustering or had greater than 10 %
outliers were not included in the study.
Unsupervised analysis
Unsupervised analysis was performed to further ascer-
tain the quality of datasets and identify outliers without
biological relevance, based on inter-array correlations
using principal component analysis (PCA; prcomp mod-
ule from the stats package in R). PCA projects multivari-
ate data objects onto a lower dimensional space while
retaining as much of the original variance as possible
[20, 21]. PCA methodology captures the inherent gene
Table 1 List of pancreatic ductal adenocarcinoma omics datasets used in multidimensional analysis
Dataset Platform Samples Reference
accession ID Normal Pancreatic cancer (PMID)
mRNA GSE15471 Affymetrix Human Genome U133 Plus 2.0 36 36 19260470
GSE28735 Affymetrix Human Gene 1.0 ST 45 45 22363658
GSE41368 Affymetrix Human Gene 1.0 ST 6 6 24120476
GSE43797 Illumina HumanHT-12 V4.0 expression bead chip 5 6 24072181
miRNA GSE24279 Febit human miRBase v11 22 136 NA
GSE29352 Febit Homo sapiens miRBase 13.0 plus 20 14 NA
GSE41369 NanoString nCounter Human miRNA assay (v1) 9 9 24120476
GSE43796 Agilent-031181 Unrestricted_Human_miRNA_V16.0_Microarray 5 6 24072181
Epigenome GSE49149 Illumina HumanMethylation450 Bead Chip 29 167 24500968
PAAD (TCGA) Illumina Infinium Human DNA Methylation 450 6 6 NA
Survival GSE21501 Agilent-014850 Whole Human Genome Microarray 132 20644708
GSE32676 Affymetrix Human Genome U133 Plus 2.0 Array 25 7 22261810
NA not available, PMID PubMed ID
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expression patterns in the data and identifies the cor-
relation among biologically distinct samples.
Supervised analysis to identify differentially expressed
molecules
We used the limma package [22] from the Bioconductor
project to identify differentially expressed molecules
(genes, miRNA or methylation) between pancreatic cancer
and normal samples. The sample groups were compared
by fitting a linear model for each variable (normalized
expression values) and applying empirical Bayes
smoothing to identify differentially expressed mole-
cules. The molecules with absolute fold change ≥ 2 and
multiple test corrected (51) P-value < 0.05 were consid-
ered significantly differentially expressed in this con-
ventional analysis approach. The list of differentially
expressed molecules from each dataset was compared
using Venn diagrams created using jvenn [23] (Add-
itional file 2: Figure S2).
Meta-analysis of data from the epigenome, transcriptome
and regulatory miRNA
Meta-analysis was performed to identify the differentially
expressed molecules from multiple datasets using a
rank-based approach (i.e., RankProd [24, 25]) in the
meta-analysis of microarray (MAMA) R package [26].
RankProd is a non-parametric statistical method that
uses the ranks of differentially expressed molecules
(between conditions compared) to obtain the com-
bined signature from multiple studies. The fold
change of genes from individual studies is trans-
formed to rank of genes across studies, and genes that
are consistently differentially expressed in multiple
studies are ranked highly. The false-positive predic-
tions were restricted to less than 5 % [false discovery
rate (FDR) ≤ 0.05], based on 1000 class label-based
random permutations. The differentially expressed
genes were identified only on the basis of the FDR P-
value without any fold change restrictions. The rank
products method provides a robust way to overcome
heterogeneity among datasets and reduces loss of use-
ful data, which is a major problem associated with the
traditional methods of finding consensually differen-
tially expressed genes after strict cutoff-based filtering
of differentially expressed genes in individual datasets
(see previous section).
Similar rank products-based meta-analysis was per-
formed on multiple regulatory miRNA expression datasets
and epigenome datasets to obtain PDAC meta-signatures
of regulatory miRNAs and differential methylation,
respectively. These gene, miRNA and methylation meta-
signatures constitute the multidimensional PDAC sig-
nature used for further analysis.
Defining interactions between multiple omics dimensions
Transcriptome–epigenome interactions
To determine the interactions between the epigenome
and transcriptome, the genes and methylations sites
were annotated using official HUGO gene symbol (ver-
sion hg19 of the human genome). The interactions be-
tween methylation and gene expression signatures were
deduced based on consensus genes found in both gene
and methylation meta-signatures. These genes, which
show differential expression as well as hypo/hyperme-
thylation, are considered to be the genes regulated by
methylation (methylation-regulated genes) irrespective
of the directionality of gene expression or methylation.
Biplots of gene expression changes with either methyla-
tion or miRNA expression changes were generated to ex-
tract any patterns between expression profiles (Additional
file 3: Figure S3).
Transcriptome-regulatory miRNA interactions
The miRNA–gene interactions were determined using
the RmiR package [27] from Bioconductor. The algo-
rithm performs consensus miRNA and target gene inter-
action prediction using multiple algorithms (e.g.,
miRBase and targetScan) to reduce the chance of false-
positive results. The miRNA and target predictions were
performed using PDAC gene expression and miRNA
meta-signatures identified from the analysis described
above. The patterns of expression between target genes
and miRNA were determined by generating biplots on
the basis of fold change of differentially expressed tar-
geted genes and interacting miRNAs. It was not clear if
all these interactions were functional in PDAC as the
known interactions were obtained based on sequence
similarity. To obtain functional interactions in PDAC
from among all the predicted interactions identified
using RmiR analysis, an additional filter was applied
based on the correlation found between gene and
miRNA expression data from the same tissue samples in
a previous multi-omics study [28]. The differentially
expressed genes and miRNAs depicting significant cor-
relation at the expression level calculated using the cor
function in R (R ≥ 0.8 or R ≤ –0.8) were considered the
functional gene–miRNA interactions. Further, the genes
that were regulated both by methylation and miRNA
were considered genes under multiple regulatory con-
trols (GMCs).
Pathway and functional analyses
To identify biological pathways significantly overrepre-
sented in miRNA-regulated and methylation-regulated
genes, pathway enrichment analysis was performed using
Ingenuity Pathway Analysis (IPA) (Qiagen) software. The
knowledge base of this software consists of functions,
pathways and network models derived by systematically
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exploring the peer-reviewed scientific literature. It calcu-
lates the P-value using Fisher’s exact test for each path-
way and functional category, according to the fit of the
user’s data to IPA databases. The P-value measures how
likely the observed association between a specific path-
way/function and the dataset would be if it were due
only to random chance. The functional categories and
pathways with FDR < 0.05 were considered to be signifi-
cantly associated.
Systems biology analysis
The meta-signatures of miRNA, genes and methylation
were utilized in generating the network of interacting
molecules from multiple omics domains using Cytoscape
2.8, an open source platform for biomolecular network
visualization [29]. The gene interaction network was cre-
ated using the Michigan Molecular Interactions (MiMI)
plugin for Cytoscape [30]. The network was created
based on molecular interactions from multiple biological
interaction databases like BIND, BioGRID, CCSB at Har-
vard, cPath, DIP, GO, HPRD, IntAct, InterPro, KEGG and
PubMed [30]. The gene–miRNA interactions were ob-
tained using RmiR analysis as previously described and in-
corporated in the comprehensive network generation
process from multidimensional PDAC meta-signatures.
The methylation meta-signature was not included at this
step because it was redundant to our eventual goal of cre-
ating a network of GMCs. Subsequently, a comprehensive
GMC (CGMC) network was extracted from the global
multidimensional PDAC meta-signature network, con-
taining GMCs along with their first interactive neighbors.
The first neighbors were included to build a cohesive net-
work around the GMCs because the GMCs themselves
represent isolated hubs. Network-based pathways enrich-
ment analysis was performed using the GeneMANIA [31]
plugin in Cytoscape. Significant pathways associated with
subnetworks of selected genes were determined using the
FDR-adjusted hypergeometric test-based Q-values re-
ported by GeneMANIA for a query gene-based search for
pathways enrichment.
Identification of key regulatory molecules from the CGMC
network
The network topological parameters were calculated
using the CentiScaPe Plugin [32] in Cytoscape. Topo-
logical analysis was performed on the CGMC network
to identify nodes that are critical for network stability.
We performed topological analysis using node stress and
neighborhood connectivity parameters from CentiScaPe
to calculate an average rank (AR) score for each node.
Node stress is a node centrality index calculated by
measuring the number of shortest paths passing through
a node [33]. The neighborhood connectivity of a node n
is defined as the average connectivity of all neighbors of
n [34]. The AR score was determined by the average
rank of the nodes with respect to these two indices. The
nodes with AR score cutoff ≤10 were considered to be
KR hubs.
Partitioning around medoids analysis
Partitioning around medoids (PAM) [35] is a robust
clustering method for partitioning based on a dissimilar-
ity matrix. We used PAM implementation from the clus-
ter package in R to partition the CGMC network around
the identified KR hubs based on Euclidean distance of
CGMC network gene expression matrix.
Gene set enrichment analysis
Gene set enrichment analysis (GSEA) [36] was per-
formed (using the javaGSEA desktop application) on the
CGMC network to determine the importance of the KR
subnetworks (gene sets) created using PAM analysis.
The GSEA algorithm determines whether a gene set is
specifically enriched at the leading edges of a reference
gene list sorted with respect to specified parameter of
interest (class-based t-test statistic). The edges of the
ranked list contain the most discriminatory genes in the
gene list and the gene sets depicting overlap with these
edges are significant. The significance of gene set enrich-
ment was determined on the basis of 1000 class-based
permutation tests [37]. Gene sets with multiple test-
corrected P-values less than 25 % (FDR ≤ 0.25) were con-
sidered significant.
Self organizing map clustering and survival analysis of
key regulatory genes
To identify group-dependent patterns from the expres-
sion profiles of KR hubs identified using systems-level
approaches, the self organizing map (SOM) clustering
technique was adopted [38]. SOM allows the grouping
of gene expression patterns into an imposed structure in
which adjacent clusters are related, thereby identifying
sets of samples that follow certain expression patterns
across KR hubs. We performed sample-based SOM clus-
tering (som package in R) using Pearson correlation
coefficient-based distance metrics to form two sample
clusters with very distinct expression profiles of KRs.
Survival analysis was performed on these clusters using
the Kaplan–Meier analysis from the survival package in
R [39]. Survival analysis was also performed on indi-
vidual KRs. The Kaplan–Meier estimate is a non-
parametric maximum likelihood estimate of the survival
function created based on the number of survivors and
non-survivors at any given time point. The results of the
survival analysis were visualized using a Kaplan–Meier
survival curve. The significance of difference in survival
among different groups was estimated using log-rank
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testing. The results were considered significant if the P-
values from the log rank test were less than 0.075.
Results
Meta-analysis of the epigenome, transcriptome and
regulatory miRNA in pancreatic ductal adenocarcinoma
Pancreatic cancer data from multiple biological domains
(omics data types) were integrated to generate a multidi-
mensional PDAC signature associated with disease
progression. The study included 177 gene expression
profiles, 224 miRNA expression profiles and 210 DNA
methylation profiles from different pancreatic cancer
studies. Details about the datasets from which these pro-
files were obtained can be found in Table 1. After
normalization and preprocessing, the individual datasets
were analyzed using unsupervised and supervised ana-
lysis methods.
Gene expression meta-signature associated with pancreatic
ductal adenocarcinoma
The unsupervised analysis from transcriptome data
using PCA showed good separation between normal and
cancer samples (Fig. 1a). In all datasets, normal and
PDAC samples were separated with the highest variation
(32–61 %) along the first principle component (PC1).
Supervised analysis was performed on each dataset to
identify differentially expressed genes between normal
and PDAC samples using limma. The analysis identified
differentially expressed genes in individual gene expres-
sion datasets that achieved a FDR ≤ 0.05, and an absolute
fold change between normal and PDAC ≥ 2. This indi-
vidual dataset-based differential expression analysis
yielded gene lists with non-significant/small overlap (106
genes out of 5421 total genes) among the datasets
(Additional file 2: Figure S2A), indicating heterogen-
eity among datasets.
Rank-based meta-analysis using the rank products
(RP) method was performed to address this inherent
heterogeneity among datasets. RP performs a rank-based
comparison of genes from different experiments to iden-
tify genes that are consistently ranked high (upregulated)
and low (downregulated), clearly depicting advantages
over linear modeling-based methods in meta-analysis by
better handling noise from heterogeneous datasets. The
RP-based method depicts a slightly better overlap among
differentially expressed genes identified in meta-analysis
(Additional file 2: Figure S2A). Owing to this better
overlap and the inherent advantage of RP in handling
noise, we adopted RP as opposed to limma for meta-
analysis. We obtained a transcriptome-specific signature
of 5391 genes that were consistently significantly differ-
entially expressed (FDR ≤ 0.05) in PDAC compared to
normal among all the datasets. A subset of top differen-
tially expressed genes obtained from meta-analysis is
shown in Fig. 1b. It is evident from the heatmap that differ-
entially expressed genes identified from the meta-analysis
are consistently over-expressed or under-expressed across
all datasets. Many of these differentially expressed genes
were initially unidentified because of filtering criteria, but
selection using rank-based meta-analysis retained them
appropriately. The most downregulated genes identified
included genes involved in basic metabolism and func-
tioning of pancreatic cells, for example, SYCN involved in
exocytosis in pancreatic acinar cells, FAM3B involved in
controlling basal insulin secretion in pancreatic beta cells,
and many enzymes involved in protein processing and
amino acid metabolism. The consistently upregulated
genes include genes linked to cell cycle progression (e.g.,
S100A11), cytoskeletal reorganization (e.g., FNBP1 and
CAPZB), kinetochore formation and spindle checkpoint
(e.g., ZWINT), immune and inflammatory response (e.g.,
IL2RG, IL8 and CXCL5), angiogenesis (e.g., PLXDC2) and
metalloproteinase (e.g., ADAM8). It was previously shown
in a meta-analysis of PDAC expression data that many of
these genes are indeed differentially expressed in PDAC
[40]. Of the 51 genes shown in that study as potential
PDAC biomarkers, 38 were also enriched in our meta-
analysis results, including S100A11, ADAM8 and IL8.
miRNA meta-signature associated with pancreatic ductal
adenocarcinoma
Supervised and unsupervised analyses were performed
on normalized miRNA datasets. PCA results showed
good separation of PDAC and normal samples along the
first three PCs in all datasets (Fig. 2a). PC1 accounted
for 10.8–34.7 % of the variance and depicted a signifi-
cant separation of PDAC and normal samples. As with
gene expression data, individual dataset-based differential
expression analysis yielded very few miRNAs that
were common among the datasets (Additional file 2:
Figure S2B), necessitating rank-based meta-analysis.
The miRNA meta-analysis identified 109 consistently
significantly differentially expressed miRNAs in PDAC
compared to normal, with FDR ≤ 0.05 (miRNA PDAC
meta-signature). A heatmap of the top differentially
expressed miRNAs obtained from meta-analysis is
shown in Fig. 2b. The heatmap clearly depicts uniform
upregulation or downregulation of different miRNAs
across 3 out of 4 datasets. MiRNAs miR-148a and miR-
375 were significantly downregulated, whereas miR-93,
miR-21, miR-10a, miR-107 and miR-23a were signifi-
cantly upregulated in PDAC. Sun et al. found a similar
dysregulation of miR-148a, miR-375, miR-21 and miR-
10a in PDAC [41]. It was shown that miR-10a could be
involved in the tumor invasiveness through HOXA1 sup-
pression in PDAC [42]. Our results are consistent with
previous findings based on GEO and TCGA data, that
miR-21 is a potential biomarker in pancreatic cancer
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Fig. 1 Meta-analysis of pancreatic ductal adenocarcinoma (PDAC) transcriptome data. a Unsupervised principal component analysis plots across
the first three principle components (PC) on individual datasets included in the meta-analysis. The variance captured by each PC is shown along
the respective axis. PDAC samples are represented in red and normal samples in black. In all datasets, PDAC and normal samples formed separate
clusters marked with ellipses. b Heatmap of fold change (Fc) of top 100 significantly differentially expressed genes identified from meta-analysis
(abs(Fc)≥ 2 in at least one of the datasets; false discovery rate≤ 0.05). Datasets are shown as columns and genes are shown as rows. Relative fold
changes are shown with a pseudocolor scale (–1 to 1), with red denoting upregulation and green denoting downregulation
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[43]. miR-107, miR-222 and miR-148a are differentially
expressed in pancreatic cancer and miR-222 is also
known to be associated with poor survival probabilities
[43].
Epigenetics meta-signature associated with pancreatic
ductal adenocarcinoma
Unsupervised analysis of normalized DNA methylation
data depicted a significant separation between PDAC
and normal samples along the top three PCs in PCA
(Fig. 3a). Out of three components, PC1 alone accounted
for 18.7 % and 46.8 % variance between PDAC and normal
samples in the two methylation datasets. The methylation
signature in PDAC constituted 2081 genes that were sig-
nificantly hyper-methylated or hypo-methylated in PDAC
compared to normal (FDR < 0.05). The heatmaps of gene
expression values for significantly differentially methylated
genes with mean methylation ≥ 0.5 and standard devi-
ation ≥ 0.2 among the top 100 genes identified from RP
analysis are shown in Fig. 3b. The top hypo-methylated
genes included CUX1, a member of the homeodomain
family of DNA binding proteins, with a probable role in
cell proliferation and cell cycle progression; CABLES1, in-
volved in cell cycle regulation through interactions with
cyclin-dependent kinases [44]; RASA3, a Ras GTPase acti-
vator involved in the control of cellular proliferation;
Fig. 2 Meta-analysis of pancreatic ductal adenocarcinoma (PDAC) regulatory miRNA data. a Unsupervised principal component analysis plots
across the first three principle components (PC) on individual miRNA datasets included in the meta-analysis. The variance captured by each PC is
shown along the respective axis. PDAC samples are represented in red and normal samples in black. In all datasets, PDAC and normal samples
formed separate clusters marked in ellipses. b Heatmap fold change (Fc) of top 50 significantly differentially expressed miRNAs identified
from meta-analysis (abs(Fc) ≥ 2 in at least one of the datasets; false discovery rate ≤ 0.05). Datasets are shown as columns and miRNAs as
rows. Relative fold changes are shown with a pseudocolor scale (–1 to 1), with red denoting upregulation in PDAC and green denoting
downregulation
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WIPF1, involved in cytoskeletal organization; STK17B, a
serine/threonine kinase acting as a positive regulator of
apoptosis; and TGFBR2, involved in multiple processes re-
lated to cell proliferation, differentiation, immunity and
carcinogenesis in the cell. Many genes involved in special-
ized cellular functions were found to be hyper-methylated,
for example, PRKCB, (protein kinase C), which plays an
important role in B-cell activation; HOXD6 belonging to
the homeobox family of genes; NTM, a neural cell adhesion
molecule; and IGF2BP1 (insulin-like growth factor 2), an
mRNA binding protein involved in translational regulation.
The multidimensional PDAC signature consists of all
significantly differentially expressed genes, miRNAs and
methylation sites in PDAC identified from the meta-
analyses (FDR ≤ 0.05) as described above.
Understanding gene–miRNA and gene–epigenetic
bimodal interactions associated with pancreatic ductal
adenocarcinoma
The meta-analysis of transcriptome, epigenome and
regulatory miRNA expression identified a large list of
differentially expressed molecules associated with PDAC.
Even though the results provide a significant starting
point for understanding disease pathophysiology, it is
difficult to pin down disease-driving molecules from
long lists of genes without considering the interaction
between molecules. To obtain this integral cross-talk be-
tween the differentially expressed molecules, the bi-
modal interactions of genes with miRNAs and genes
with methylation were first interpreted. The cross-talk
between differentially expressed genes and miRNAs was
Fig. 3 Meta-analysis of pancreatic ductal adenocarcinoma (PDAC) epigenome data. a Unsupervised principal component analysis plots across the
first three principle components (PC) on individual DNA methylation datasets included in the meta-analysis. The variance captured by each PC is
shown along the respective axis. PDAC samples are represented in red and normal samples in black. In all datasets, PDAC and normal samples
formed separate clusters marked in ellipses. b DNA methylation heatmaps show the expression matrix of genes with mean methylation≥ 0.5 and
standard deviation≥ 0.2 among the top 100 differentially methylated genes identified by rank products analysis (false discovery rate≤ 0.05) from
each dataset used in the meta-analysis. Samples are shown as columns and genes as rows. Relative methylation is shown with a pseudocolor scale
(–1 to 1), with red denoting relatively high expression in PDAC and green relatively low expression across row-scaled data
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deduced on the basis of sequence homology-based
miRNA target gene prediction. Based on predicted
gene–miRNA targets, 1150 genes were identified to
interact with 49 miRNAs from the PDAC meta-gene sig-
natures and, hence, expression of these genes is potentially
regulated by miRNAs (i.e., they are miRNA-regulated
genes) (Fig. 4a).
The interaction between PDAC-associated gene ex-
pression and methylation changes was deciphered by
comparing the differentially expressed and differen-
tially methylated genes on the basis of HUGO gene
symbols. Among the PDAC gene meta-signature, 715
genes showed overlap with the methylation meta-
signature and were considered to be methylation-
regulated genes (Fig. 4a).
The inverse proportionality postulate between control
mechanisms and gene expression was tested by generating
biplots of gene expression changes with either methy-
lation or miRNA expression changes (Additional file 3:
Figure S3). The predicted miRNA–gene interactions
showed no direct or inverse correlation between gene
and miRNA expression. Methylation biplots showed
that hyper-methylation was associated with both up-
regulation and downregulation of gene expression. On
the other hand, hypo-methylated genes (70 out of the
715 methylation-regulated genes) were mostly upregu-
lated at the gene expression level (Fig. 4b). These re-
sults reinforce that the control mechanisms on gene
expression are complex multi-level interactions and
hence it is not possible to find a simple one-to-one
relationship at a molecular level.
There were 189 genes that were common between the
miRNA-regulated and methylation-regulated genes
(Fig. 4a.) and thus are classified as genes under multiple
Fig. 4 Identification of genes under miRNA and epigenetic control. a Venn diagram showing the overlap between differentially expressed genes
regulated by differential methylation and miRNA. The analysis identified 189 genes that are under multiple regulatory controls (GMCs), which
means that these genes are altered at gene expression, regulatory miRNA and methylation levels. b Hierarchical interaction of GMCs depicting
gene expression, miRNA and epigenetic level alterations of molecules. The nodes represent the GMCs (circles) and the regulatory miRNA
molecules (V-shape) and edges depict regulatory interactions. Each gene is dual colored based on expression change (log2FC, left side) and
differential methylation (right side). Red denotes upregulation and green denotes downregulation in PDAC compared to normal. The figure also
contains results from pathways enrichment analysis of (c) methylation-regulated genes and (d) miRNA-regulated genes. The y-axis represents
significantly effected canonical pathways and x-axis the –log transformed Fisher’s exact test P-value. The common pathways are marked with
red asterisks
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regulatory controls (GMCs). Among the GMCs, the
gene expression signature was ~70 % inversely corre-
lated with the methylation signature, as expected, but
the miRNA interactions did not show any significant
pattern. This is probably because the miRNA–gene in-
teractions were predicted on the basis of sequence simi-
larity but have not been verified experimentally in
pancreatic cancer. Furthermore, it has been suggested
the gene–miRNA interactions do not necessarily have to
be mechanisms for gene regulation, but could instead
act as mechanisms for modulating cellular miRNA levels
(sponge interactions) [45]. To understand this complex-
ity and identify the functional gene–miRNA interactions
in PDAC, we analyzed a PDAC dataset containing
sample-matched gene and miRNA expression profiles
[28, 46]. We identified the functional gene–miRNA in-
teractions on the basis of correlation analysis of the 49
miRNAs with 1150 predicted gene targets, previously
identified from the sequence similarity-based prediction.
The analysis identified 36 functionally relevant miRNAs
that interact with at least one of the 189 GMCs. A hier-
archical network of GMCs and their functionally rele-
vant miRNA regulators is shown in Fig. 4b. The GMC
nodes are dually colored for gene expression and methy-
lation, showing largely inverse correlation, and the miR-
NAs are colored based on their differential expression
values.
The results from functional gene–miRNA interaction
analysis show that miR-210 and miR-222 are upregulated
in PDAC and are correlated with many of the GMCs
(Fig. 4b). The role of miR-210 has been extensively stud-
ied in connection with hypoxia in the tumor micro-
environment in many solid tumors, including pancreatic
cancer, and its oncogenic role in cancer progression is
being explored [47]. Similarly, miR-222 has been shown
to be involved in epithelial-to-mesenchymal transition
(EMT) in breast cancers, leading to an aggressive breast
cancer phenotype [48]. The miRNAs miR-194 and miR-
195, known to be involved in anti-tumor mechanisms in
the cell, are downregulated in our PDAC signature and
correlated with many of the identified GMCs in our
study. For example, miR-194 is an epithelial marker and
is known to target many genes involved in the epithelial-
to-mesenchymal transition, thereby reversing the transi-
tion [49], whereas miR-195 has been shown to induce
apoptosis in human embryonic stem cells of neural ori-
gin [50].
The comparison of methylation-regulated and miRNA-
regulated genes on the basis of significantly impacted
(-log(P-value) ≥ 10) functional categories revealed a con-
siderable overlap between the two sets. Commonly af-
fected functional categories include cellular growth and
proliferation, cellular development, cellular movement,
cell death and survival, organismal survival, organismal
development, embryonic development, cancer, gastro-
intestinal disease, and cardiovascular system development
(Additional file 4: Figure S4). Methylation-regulated genes
uniquely associated with pro-inflammatory and immune
response-related pathways like the IL-1, IL-8 and NFκB
signaling pathways. They were also enriched in pathways
involved in cancer invasiveness and cellular motility, such
as leukocyte extravasation, glioma invasiveness and Paxil-
lin signaling pathways (Fig. 4c). The pathways specific to
miRNA-regulated genes involved normal developmental
pathways that regulate cell survival, cell proliferation and
angiogenesis, such as TGFβ, HGF, Wnt and STAT3 signal-
ing pathways (Fig. 4d). Similar to the functional categories,
we also observed a significant overlap in enriched ca-
nonical pathways between methylation-regulated and
miRNA-regulated genes, including PTEN, integrin and
axonal guidance signaling pathways (marked with aster-
isk in Fig. 4c, d).
Interestingly, PTEN signaling, a potent pathway associ-
ated with progression and aggressiveness in multiple
cancers, depicted significant dysregulation at gene ex-
pression, miRNA and methylation levels (Fig. 5a). PTEN
is a tumor suppressor gene that functions as a phosphat-
ase and regulates signaling pathways involved in cell
growth, migration and apoptosis. PTEN-inactivating mu-
tations have been associated with many cancers includ-
ing prostate, breast, brain and kidney cancers. Even
though PTEN itself is not significantly dysregulated in
our PDAC meta-signatures, many genes downstream of
PTEN are significantly dysregulated and pathways that
would be inhibited by PTEN under normal conditions
are significantly upregulated. For example, both FAK-
CAS and Ras-Raf-MAPK signaling cascades involved
in cell migration are upregulated, as is the AKT sig-
naling pathway associated with cell survival (Fig. 5a).
A heatmap of differentially expressed molecules (gene
expression and methylation) involved in the PTEN
pathway is shown in Fig. 5b, in which the miR-
regulated genes are marked. Given that multiple miR-
NAs are known to interact and regulate these genes,
individual miRNAs are not indicated in the heatmap.
The methylation-based and miRNA-based regulations
are occurring in different subsets of PTEN pathway
genes, with only ITGA3 and TGFBR3 under multidi-
mensional control (Fig. 5b). The hyper-methylated
genes, namely PI3K, GFR, SHIP and MAGI-2, are
downregulated, as would be expected, while PDK1
and MAST2 are both hyper-methylated and upregu-
lated. Even though PI3K is downregulated, the func-
tions mediated by AKT and other downstream
effectors suggest pro-survival. miRNA-mediated regu-
lation is evidenced in the Ras-Raf-MAPK signaling
cascade associated with cell migration and in pro-
survival through AKT and BCL2 [51].
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Systems biology analysis of the network of genes under
multiple regulatory controls and identification of key
regulatory hubs
One of the major shortcomings of the traditional ap-
proach is the assumption that the highly differentially
expressed genes play causal roles in disease processes
without differentiating driver and passenger gene ex-
pression changes. Multiple-systems biology studies have
shown that the key driver genes, those playing a causal
role in initiating signaling cascades that result in mul-
tiple highly differentially expressed genes, are only mod-
erately altered in cancer and are not identified by the
conventional approaches based on degree of differential
expression [52]. There is also the task of narrowing
down to a few critical genes from a long list of differen-
tially expressed genes identified from these approaches.
The bimodal filtering of differentially expressed genes
based on alteration of upstream regulatory controls de-
veloped in this study assists in identifying a set of candi-
date genes with the fewest false positives and a high
potential of association with disease pathophysiology. It
is hypothesized that these perturbations that channel
through multiple genomic spaces are the ones that
perform regulatory bottle-neck roles in driving disease
progression and might provide better diagnostic/prog-
nostic or therapeutic biomarkers [53]. We took a
systems-level approach to address the scale-free nature
of biological systems in which a few key hubs regulate a
majority of the other genes in the network [54]. The dir-
ectionality of flow of perturbations can also be identified
from this network-based approach and this is important
in isolating the causal changes from all other cancer-
associated changes.
The multidimensional PDAC meta-signatures were
used to create a global network of 3386 nodes on the
basis of available interactome information (Fig. 6a). To
focus on GMCs and their interactants, a comprehensive
subnetwork of 711 nodes consisting of GMCs and their
first neighbors was extracted from this network (Fig. 6b).
To understand the molecular processes affected by this
CGMC network, we performed Fisher’s exact test-based
over-representation analysis using IPA software (Qia-
gen). The analysis showed that the CGMC network
genes were involved in many critical cellular functions
related to cell cycle, growth factor signaling, apoptosis,
cancer, organismal growth and proliferation, and
Fig. 5 Genes under multiple regulatory controls in the PTEN pathway. a PTEN signaling pathway showing differentially expressed genes
(red = upregulation, green = downregulation). b Heatmap showing differential expression (log2Fc) and differential methylation of dysregulated
genes involved in the PTEN pathway. The pathway genes interacting with multiple miRNAs are marked (miR-controlled genes; orange stars).
Dysregulated genes in the PTEN pathway are shown as rows and columns show differential gene expression, differential methylation and
miRNA-interaction, respectively. Relative fold changes are shown with a pseudocolor scale (–1 to 1), with red denoting gene upregulation or
hyper-methylation and green denoting gene downregulation or hypo-methylation
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immune response (Additional file 5: Figure S5). Among
the cell cycle-related pathways, integrin signaling (P-
value = 6.3E − 19) was the top enriched pathway with
positive z-score indicating pathway activation. The TGFβ
signaling pathway (P-value = 1E − 14) was the most acti-
vated and the HGF signaling pathway (P-value = 8E − 13)
the most inhibited among the growth factor signaling
pathways. It has been shown from analysis of TCGA
RNA-seq data that TGF-β signaling is active in the PDAC
transcriptome signature [55]. PTEN signaling (P-value =
1.9E − 14) was downregulated and was the top enriched
pathway among apoptosis-related pathways. Among
the cancer-related pathways, colorectal metastasis signal-
ing (P-value = 1.9E − 16) and PDAC signaling (P-value =
1E − 13) were among the most enriched. Axonal guidance
signaling and regulation of the epithelial–mesenchymal
Fig. 6 Functional gene networks of genes under multiple regulatory controls (GMCs). a Global network of interacting molecules obtained from
multidimensional pancreatic ductal adenocarcinoma (PDAC) meta-signatures. b Comprehensive GMC (CGMC) network containing GMCs and their
first neighbors extracted from global multidimensional PDAC network. The key regulatory hubs in the CGMC network are highlighted in yellow.
Subnetworks (I, II, III, IV and V) of the top five key regulators (E2F3, NUAK1, ACTN1, RASA1 and SKI) were identified from topological analysis of the
CGMC network. The network genes are represented as circles and miRNAs as hexagons. Upregulated molecules are shown in shades of red while
downregulated molecules shown in shades of green
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transition were the top enriched organismal growth
and proliferation-related pathways. Multiple immune
response-related pathways were enriched in CGMC
network genes: IL-8 and leukocyte extravasation sig-
naling pathways were activated whereas the CXCR4
signaling pathway was downregulated (P-value range
= 3.9E − 15 to 3.16E − 10).
KR hubs were identified from the CGMC network
through topological analysis on the basis of node inter-
actions. The nodes were ranked based on neighborhood
connectivity and node stress. From this analysis, eight
KR hubs were identified (AR score ≤ 10), namely E2F3,
HMGA2, RASA1, IRS1, NUAK1, ACTN1, SKI and DLL1.
The top five hubs according to the AR score are shown
in Fig. 6b (I–V). To understand the biological role of
these KR hubs, we created KR subnetworks constituting
these KR hubs along with their first neighbors and per-
formed functional enrichment analysis of these subnet-
works. E2F3 is a top-ranking KR hub with 24 interacting
neighbors that were significantly linked with G1/S tran-
sition of the mitotic cell cycle (FDR = 0.0021). The
NUAK1 subnetwork consisted of 17 neighbors associ-
ated with the TLR signaling pathway (FDR = 0.00041).
Previous studies have shown that tumor cells express
functional TLRs and their activation leads to tumor cell
proliferation and resistance to apoptosis [56]. The
ACTN1 subnetwork had 22 interacting neighbors signifi-
cantly associated with cell adhesion and cell junction
organization (FDR = 8.57E − 05). The RASA1 hub had 34
interacting neighbors involved in many growth response
signaling pathways like ERBB signaling (FDR = 4.71E −
11). SKI interacted with 13 neighboring nodes in the
CGMC network and was involved in endocrine system
development, pancreas development and negative regu-
lation of TGFβ receptor signaling (FDR = 5.07E − 05).
Enrichment of key regulatory subnetworks in the overall
comprehensive genes under multiple regulatory controls
network
The importance of the identified KRs in the CGMC net-
work was assessed using a GSEA approach. The analysis
was designed to understand the importance of subnet-
works created from eight identified KRs in the overall
CGMC network. The KRs were used as seeds to parti-
tion the CGMC network into PAM clusters using the k-
medoids clustering methodology. This methodology
identifies subnetworks on the basis of correlation of KRs
with other genes in the network instead of just taking
into consideration the first neighbors of KRs. The en-
richment of these KR clusters in the CGMC network
was assessed using GSEA. Six of the eight KR clusters
showed statistically significant enrichment (nominal
P-value ≤ 0.05 and FDR ≤ 0.25) (Table 2), confirming that
these KRs and their correlated genes (KR subnetworks)
comprise the most altered genes in PDAC among the
CGMC genes. Figure 7 shows the GSEA enrichment plots
of the top four of these KR clusters, namely IRS1, E2F3,
DLL1 and SKI. The IRS1 cluster had the highest positive
enrichment score (normalized enrichment score = 2.74)
and the DLL1 cluster had the highest negative enrichment
score (normalized enrichment score = −3.1). ACTN1 and
HMGA2 clusters showed a general overall distribution of
genes in the network skewed more towards the upregu-
lated genes. SKI showed a similar trend but skewed more
towards the downregulated genes in the network. The re-
sults clearly show that even though we started with a set
of differentially expressed genes that were not filtered
based on fold change, the KRs and their subnetworks are
formed from substantially differentially expressed genes.
This subnetwork enrichment analysis has provided a way
to understand the relative importance of the identified
KRs in stabilizing PDAC network. The analysis also
showed that IRS1, E2F3, DLL1, SKI, ACTN1 and HMGA2
are correlated with genes that are more differentially
expressed in PDAC compared to RASA1 and NUAK1.
Survival analysis of identified key regulators in pancreatic
cancer
The significance of the KRs was further tested using sur-
vival analysis on the eight identified KRs in two PDAC
expression datasets. The samples were partitioned into
two groups by the most contrasting expression charac-
teristics for the eight KRs using the SOM clustering ap-
proach, and survival analysis was performed on the two
clusters (Additional file 6: Figure S6; Ai. and Bi). The re-
sults showed that the KRs were able to clearly discrim-
inate between better versus poor survivors (P-values
0.0368–0.0464), indicating their prognostic role in
PDAC.
Table 2 Gene set enrichment analysis of KR-PAM clusters
Name Size ESa NESb Nom P-valuec FDR q-valued
IRS1 47 0.814297 2.749994 0 0
E2F3 83 0.538403 2.012985 0 0
ACTN1 197 0.364171 1.523528 0 0.018332
HMGA2 75 0.401607 1.467728 0.0122378 0.020817
NUAK1 26 0.332612 1.002291 0.4466912 0.4542
DLL1 57 −0.90119 −3.20045 0 0
SKI 133 −0.42133 −1.72121 0 0.001876
RASA1 93 −0.19612 −0.75914 0.9367682 0.91951
aES Enrichment score showing the maximum deviation from zero based on
Kolmogorov-Smirnov statistic
bNES Normalized enrichment score calculated from a null distribution created
from 1000 permutations of phenotype labels
c Nominal P-value obtained from the null distribution
d Multiple test corrected P-value
FDR false discovery rate
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To further ascertain the relative importance of these
eigth identified KRs in survival, we performed survival
analysis on individual KR genes. In the individual gene-
based survival analysis, HMGA2, IRS1, ACTN1, SKI and
DLL1 showed significant differences in survival probabil-
ities (log-rank test P-value ≤ 0.075) when samples were
split on the basis of low or high expression of individual
KRs (Fig. 8). The analysis showed that higher expression
Fig. 7 Determining the importance of key regulatory (KR) gene subnetworks in comprehensive genes under multiple regulatory controls (CGMC)
network using gene set enrichment analysis. The figure shows enrichment plots from the top four KR subnetworks that are significantly enriched
in the CGMC network. The significance was determined from nominal P-values (≤0.05) and false discovery rate (≤ 0.25) obtained from gene set
enrichment analysis (GSEA). Each enrichment plot shows the following: Top: running enrichment score (ES) of the gene set (KR subnetwork) as a
running-sum statistic working down the ranked list of CGMC network genes. The peak of the plot is the ES for the gene set (shown with red line).
Middle: black vertical bars show the position of genes in the KR subnetwork in the ranked list of CGMC genes. The leading edge is the subset of
genes that contribute most towards the ES and are the most differentially expressed genes in the CGMC network. Bottom: a colored bar showing
positive (red) and negative (blue) correlation to phenotype and a plot showing the ranked list of CGMC genes based on the t-test that measures
the gene’s correlation with the phenotype. Normalized enrichment score (NES) and nominal P-value (NOM) obtained from the GSEA analysis are
shown on top of each plot
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levels of IRS1 and DLL1 and lower expression levels of
HMGA2, ACTN1 and SKI were associated with signifi-
cantly higher survival probabilities. Interestingly, these
five KR genes that show higher prognostic value in
PDAC among the KRs also comprise the most enriched
subnetworks in the GSEA analysis (five out of the six
enriched KR subnetworks). E2F3, which was the other
KR that was significant in the GSEA-based subnetwork
enrichment analysis, did not reach statistical significance
in the individual survival analysis, but was able to dis-
criminate poor survivors from better survivors to some
extent. Thus 83 % of the KRs filtered through subnet-
work enrichment analysis were also found to have sig-
nificant prognostic value in the survival analysis,
indicating that our systematic filtering approach has pro-
vided a valuable set of genes that are potential biomarkers
with prognostic value in PDAC.
Discussion
One of the most challenging tasks in the analysis of
large-scale omics data is the identification of the causal
(KR) changes and differentiating them from bystander
effects associated with the disease. Owing to the large
number of genes measured in genomic assays, it is diffi-
cult to achieve statistical power except for the most
highly differentially expressed molecules. In many cases
the KRs remain unidentified owing to subtle changes at
expression level. Even when identified as being differen-
tially expressed, KRs are hard to characterize based on
just their differential expression measure from a long list
of altered molecules. However, the alternative approach
of identifying regulatory genes from biochemical studies
is laborious and time consuming and does not compare
to genome-scale experiments in providing comprehen-
sive coverage.
Numerous studies have shown that network-based ap-
proaches that take into consideration the contribution
of individual genes along with their interactions are an
effective solution in identifying KRs of disease patho-
physiology [57]. It has been hypothesized that KRs are
functional bottlenecks in disease initiation and progres-
sion because they regulate the expression of a large
number of downstream effector genes [57]. Most of
these studies performed the network analysis on gene
expression data, ignoring the contribution of upstream
regulatory genomics and epigenetics spaces. We
hypothesize that molecules whose alterations result in
upstream regulatory changes in a feedback manner as
well as in important downstream effector changes are
critical for disease progression and pathophysiology.
Keeping this in mind, we adopted a multistep ap-
proach integrating the cross-talk between different gen-
omics spaces (the epigenome, transcriptome and
regulatory miRNAs) as well as an interactive network
Fig. 8 Survival association analysis of individual key regulators (KRs) in pancreatic ductal adenocarcinoma survival plots of KRs, depicting
significant correlation (log-rank test P-value≤ 0.075) between KR expression and patient survival time. Lower expression levels of HMGA2,
ACTN1and SKI and higher expression levels of IRS1 and DLL1 were associated with better survival probabilities. The log-rank P-value between the
two groups created based on the mean or median split of the expression values of KRs is shown at the bottom of each plot
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analysis to identify the key driver genes associated with
PDAC. To achieve this, we initially performed rank-based
meta-analysis individually on epigenetic, transcriptional
and miRNA expression data to define a comprehensive
landscape of molecular alterations in PDAC. It is well
established that rank-based methods perform more reli-
ably and consistently than non-parametric and parametric
methods for meta-analysis of microarray data [24]. In this
study we implemented a rank-based meta-analysis ap-
proach, which enabled us to identify consistently differen-
tially expressed molecules from multiple studies and
increased the statistical power by eliminating false-positive
genes from individual studies while retaining consistently
differentially expressed molecules with subtle changes.
To generate a comprehensive view of alterations asso-
ciated with PDAC as well as understanding the cross-
talk among different genomic spaces, we adopted a
multidimensional modeling-based approach. This step
involved the integration of meta-analysis results from
each omics dimension (the epigenome, transcriptome
and regulatory miRNAs) and is important for under-
standing the regulatory cascades and cross-talk between
gene expression and upstream regulatory mechanisms.
Understanding of the role of these epigenetic and post-
transcriptional modifications in the development of dis-
ease phenotype could be crucial to identify regulatory
bottlenecks that play causal roles in the disease. Pro-
found epigenetic changes have been shown to associate
with the onset and progression of cancer, and changes in
DNA methylation is one of the potent underlying mech-
anisms [58, 59]. Similarly, significant dysregulation has
been reported in regulatory miRNA expression in cancer
[60, 61]. In fact, it has been shown that miR-21 and
miR-222, which formed part of our multidimensional
PDAC meta-signature, are both probable prognostic
markers for PDAC [61]. It is important to note that
miR-222 was also identified as a KR of PDAC patho-
physiology in our systems-level network analysis. In this
respect, the interactive network analysis of miRNA
subnetworks created from the global PDAC meta-
signatures network reiterated the importance of the
systems-level approach in understanding the cause–ef-
fect relationship between the dysregulated molecules
(Additional file 7: Figure S7). The analysis showed that
miRNA-221 and miRNA-222 were highly correlated and
were at the center of a subnetwork created around miR-
222 (Additional file 7: Figure S7B), while the highly dys-
regulated miRNA-210 was one of the peripheral molecules
in its subnetwork (Additional file 7: Figure S7A). In a con-
ventional analysis of dysregulated genes, all three miRNAs
would have been weighted equally in their contribution to
disease pathophysiology, whereas a systems-level analysis
clearly shows that miRNA-221 and miRNA-222 play a
more causal role than miRNA-210 in PDAC disease
progression. It was also evident from our analysis that
miR-194, an epithelial marker that is downregulated in
PDAC, is the center of the subnetwork created from miR-
210.
It has been postulated that dysregulation in regulatory
mechanisms can play important causal roles in disease
initiation and/or progression [61, 62]. In many instances,
these regulatory layers provide the missing links to ra-
tionalize the observed variance seen in gene expression.
It is also established that regulatory miRNAs are them-
selves regulated by epigenetic changes and sponge
miRNA targets [45], which would be another layer of
regulatory control that needs to be factored into our
multidimensional model in the future. We overcame this
additional complexity here by including only the miRNA
changes that were correlated with gene expression
changes from multi-omics studies with both gene ex-
pression and miRNA expression data on matched sam-
ples. Overall, in the multidimensional modeling step we
identified 189 genes that manifested concerted changes
across gene expression and their regulatory mechanisms
in pancreatic cancer. As expected, this consensus multi-
dimensional PDAC signature was enriched in important
pathways associated with cancer progression, such as
cell cycle regulation, cell growth and proliferation,
cell motility, cell-based immunity, and inflammatory
response.
Further, to understand the cause–effect relationship
and the mechanistic overview of PDAC progression, we
performed interaction network analysis on GMCs on the
basis of interactome information. This multidimensional
network was analyzed for topological cues to identify the
most probable candidates for KRs of the network and,
by extension, key disease modulators. These KR mole-
cules represent regulatory bottlenecks and play a causal
role in disease initiation and progression. The presence
of these regulatory bottlenecks in establishing disease
phenotype has been shown in multiple studies relating
to cancer [57, 63–68]. These studies showed that genes
with no prior known oncogenic status or known muta-
tions associated with a particular disease could still be
influential in controlling many disease-related genes,
and thus serve as regulatory bottlenecks that can be
identified only by a systems-level approach. In our ana-
lysis, ranking based on a node centrality measure (node
stress) and neighborhood connectivity identified eight
probable regulatory hubs in the network. Thus, our
consensus multidimensional approach along with the
systems-level network analysis resulted in a dramatic re-
duction of testable hypotheses from 6863 molecules to
eight genes. Finally, the ability to identify the KRs of dis-
ease processes independent of sample-matched omics
profiles would be a great advantage that allows, in the-
ory, the use of all available genomics data associated
Rajamani and Bhasin Genome Medicine  (2016) 8:38 Page 17 of 20
with the disease. However, this also imposes a huge re-
sponsibility of maintaining consistency in the subtype
context across the multiple dimensions of analysis to
produce meaningful and concordant results.
Conclusions
In this study we were able to isolate converging regula-
tory modules and KR molecules associated with PDAC
pathophysiology by employing a hierarchical systems-
level multidimensional data analysis approach. GSEA on
subnetworks of these KRs depicted significant enrich-
ment in the leading edges of the CGMC network genes,
suggestive of their important roles in PDAC progression.
The identified KRs were able to differentiate poor sur-
vivors from better survivors, further strengthening our
evidence that they are genes of prognostic value and
can be used as probable therapeutic targets in treat-
ment of pancreatic cancer. Data integration methods
for multidimensional data are still in their infancy, but
multi-omics integration using new experimental and
computational approaches is already producing useful
functional models and meaningful insights into disease
pathophysiology.
Additional files
Additional file 1: Figure S1. Method schematic. Schematic
representation of methodology used in the study. The major steps are
shown in gray, the methods or applications used in different steps are
indicated on the arrows leading to the outcomes of each step shown in
blue/pink. Final outcome is shown in orange. (PDF 313 kb)
Additional file 2: Figure S2. Conventional differential expression
analysis of transcriptome and regulatory miRNA compared to the RP
method. The results from traditional limma analysis on individual datasets
are shown at the top and results from the individual RP analysis at the
bottom of the figure. A Venn diagram showing the overlap of
differentially expressed genes obtained from multiple mRNA datasets
(upregulated genes shown on the left and downregulated genes on the
right). B Venn diagram showing the overlap of differentially expressed
miRNAs obtained from multiple miRNA datasets. RP analysis identified
more commonly differentially expressed genes compared to limma,
therefore RP was chosen for meta-analysis. (TIFF 21797 kb)
Additional file 3: Figure S3. Biplots of dysregulated genes with
interacting dysregulated miRNAs and differential methylation. A Biplots
showing logFc of genes along x-axis and logFc of interacting miRNAs
along y-axis. B Biplots showing logFc of genes (x-axis) and logFc of
differential methylation for the same genes (y-axis). Upregulated and
down regulated genes are denoted in red and green, respectively. A
gene–miRNA biplot showed no discernible distribution pattern while
gene–methylation biplots showed that hypomethylated genes are mostly
upregulated. (TIFF 4729 kb)
Additional file 4: Figure S4. Functional enrichment analysis of
miRNA-regulated and methylation-regulated genes. Functions associated
with (A) miRNA-regulated genes and (B) methylation-regulated genes.
The y-axis represent significantly effected functions and the x-axis
represents log-transformed Fisher’s exact test P-value. (TIFF 16066 kb)
Additional file 5: Figure S5. Pathways enrichment analysis of CGMC
network genes. Pathways associated with CGMC network genes with
a − log-transformed multiple test-corrected Fisher’s exact test P-value
(NLP) ≥10 are shown. Bar graphs showing enriched pathways (x-axis).
Pathways are sorted on the basis of multiple test corrected NLP (y-axis).
The bars are colored based on enrichment score (z-score); positive
z-scores shown in orange indicate probable activation of the pathway,
negative z-scores shown in blue indicate probable suppression of the
pathway. (TIFF 10783 kb)
Additional file 6: Figure S6. Survival association analysis of KRs in
PDAC. A Results from PDAC survival dataset 1 showing (i) partitioning of
samples on the basis of expression profile of KRs using SOM clustering
method. We identified two strikingly opposite expression patterns (black
and red ellipses). (ii) Kaplan–Meier plots showing survival association of
clusters 1 (black) and 2 (red) that correspond to the opposing expression
patterns from i. Log-rank test P-value shown on top of the survival plot.
(iii) Heatmap showing expression of KR genes in clusters 1 and 2. The
column side bars show cluster 1 (black) and cluster 2 (red). B Results from
similar analysis of PDAC survival dataset 2. In the heatmap, samples are
shown as columns and KR genes as rows. Relative expression shown with
a pseudocolor scale (−1 to 1), with red denoting relative high expression
and green denoting relative low expression in row-scaled data.
(TIFF 35079 kb)
Additional file 7: Figure S7. miRNA-centered interactive networks
obtained from dysregulated functionally relevant miRNAs in PDAC. A
Network built around miR-210 from global multidimensional PDAC
signatures network. The visual analysis of the network indicates miR-194
as a KR instead of miR-210 (thick gray outline). B Networks built similarly
around miR-221. It is centered on miR-221 and miR-222 (thick black
outline). Genes represented as circles and miRNAs as hexagons; first
neighbors of the miR-210 and miR-221 highlighted in thick blue outline.
(TIFF 26867 kb)
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